Steve Liapis

Steve Liapis, Ph.D., currently serves as Director and Principal at Northpond Ventures since November 2021, and holds multiple board positions at Garuda Therapeutics, Kyverna Therapeutics, Totus Medicines, Incendia Therapeutics, and Opna Bio, all focused on innovative therapeutic solutions for various diseases. Prior experience includes a directorial role in oncology portfolio strategy at Sanofi, head of strategy and corporate development at Arbor Biotechnologies, and engagement manager at L.E.K. Consulting, where strategic leadership was provided for over 30 biotech engagements. An academic background in molecular biology was established at Harvard University, culminating in a Ph.D., with prior studies in plant physiology and plant genetics at Yale University.